Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06601296 · ClinicalTrials.gov registry record · Phase 2
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
A Phase 2 study of Metastatic Renal Cell Carcinoma ( mRCC) and OligoProgressive Metastatic Disease, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06601296 is a Phase 2 study of Metastatic Renal Cell Carcinoma ( mRCC) and OligoProgressive Metastatic Disease that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06601296, a Phase 2 study of Metastatic Renal Cell Carcinoma ( mRCC) and OligoProgressive Metastatic Disease, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
Conditions Studied
Interventions
- DRUG IMSA101
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06601296
The ClinicalTrials.gov registry entry for NCT06601296 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Renal Cell Carcinoma ( mRCC) appearing as the primary indexed condition, and to 1 intervention - of which IMSA101 is the first listed.
NCT06601296 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06601296 about?
NCT06601296 is a clinical study titled "Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer". To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
What is the current status of trial NCT06601296?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-04-01. Estimated completion is 2028-10.
What conditions does trial NCT06601296 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease.
What interventions are being tested in trial NCT06601296?
The interventions under investigation include: IMSA101 (DRUG).
Who is sponsoring clinical trial NCT06601296?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06601296 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma ( mRCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Renal Cell Carcinoma ( mRCC)
All registered trials for this condition
OligoProgressive Metastatic Disease
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.